Peritoneal mesothelioma

Abstract

This review provides an overview of articles about peritoneal mesothelioma (PM) to analyze the effect of treatment modalities on response rates, post-treatment side effects, morbidity and mortality, and survival. Median survival in months following systemic chemotherapy (SC) ranged from 8.7 to 26.8 months. However, no patient was reported to have survived for more than five years with SC alone. In contrast, comprehensive treatment that included cytoreductive surgery (CRS) + perioperative chemotherapy (POC) showed a significantly longer median survival time than SC alone. Additionally, CRS + POC demonstrated 10-year survival rates of 12%-35%. Accordingly, CRS + POC is an innovative treatment that provides long-term survival in selected patients with PM. Selection criteria are performance status (ECOG PS ≤ 1), the absence of extraperitoneal metastasis, PCI less than cutoff levels (from < 10 to < 28), MIB-1 index (< 10), and histologic type (epithelioid type). Postoperative morbidity and mortality rates after CRS + POC were significantly higher than with more conventional operations. Accordingly, CRS and POC should be done at the specialized peritoneal surface malignancy centers.

Keywords

Peritoneal mesothelioma / mesothelioma / intraperitoneal chemotherapy / HIPEC / peritonectomy

References

[1] Mery E,Capovilia M.Peritoneal malignant mesothelioma: review and recent data.Ann Pathol2014;34:26-33

[2] Consonni D,De Matteis S.Peritoneal mesothelioma and asbestos exposure: a population-based case-control study in Lombardy, Italy.Occup Environ Med2019;76:545-53 PMCID:PMC6703122

[3] Kanarek MS.Asbestos intalc and mesothelioma: review of the causality using epidemiology.ESMED2020;8

[4] Bridda A,Mencarelli R.Peritoneal mesothelioma: a review.MedGenMed2007;9:32 PMCID:PMC1994863

[5] Carbone M,Alexander HR.Mesothelioma: scientific clues for prevention, diagnosia and therapy.CA Cancer J Clin2019;69:402-29

[6] Delgermaa V,Park EK,Hara T.Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.Bull World Health Organ2011;89:716-24 PMCID:PMC3209980

[7] Boffetta P.Epidemiology of peritoneal mesothelioma: a review.Ann Oncol2007;18:985-90

[8] Oddone E,Nava CR.Forecast of malignant peritoneal mesothelioma mortality in Italy up to 2040.Int J Environ Res Public Health2020;18:160 PMCID:PMC7796001

[9] Moolgavkar SH,Turim J.Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005.Cancer Causes Control2009;20:935-44

[10] Kusamura S,Villeneuve L.Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.Eur J Surg Oncol2021;47:36-59

[11] Verwaal VJ,Baratti D.The eligibility for local-regional treatment of peritoneal surface malignancy.J Surg Oncol2008;98:220-3

[12] Sugarbaker PH.Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.Eur J Surg Oncol2017;43:1228-35

[13] Cartenni G,Martin Garcia G.Malignant peritoneal mesothelioma-results from the international expanded access program using pemetrexed alone or in combination with a platinum agent.Lung Cancer2009;64:211-18

[14] Jänne PA,Belani CP.Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program.Clin Lung Cancer2005;7:40-6

[15] Simon GR,Janne PA.Pemetrexad plus gemcitabine as first line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II tria.J Cin Oncol2008;26:3567-72

[16] Le DT,Hunt K,Verschraegen CF.Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma.Cancer Invest2003;21:682-9

[17] Sgarbura O,Tosi D.MESOTIP: phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma.Pleura Peritoneum2019;4:20190010 PMCID:PMC6693480

[18] Fennell DA,Ottensmeier C.Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.Lancet Oncol2021;22:1530-40 PMCID:PMC8560642

[19] Tanaka T,Sakai A.Nivolumab for malignant peritoneal mesothelioma.BMJ Case Rep2020;13:e237721 PMCID:PMC7705565

[20] White MG,Xue L.Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.Br J Cancer2021;124:564-6

[21] Yonemura Y.Reasons why systemic chemotherapy cannot cure patients with cancer. In: Yonemura, Y, editor. Comprehensive treatment for peritoneal surface malignancy with an intent of cure. Asian School of Peritoneal Surface Oncology: Japanese; 2019. p. 138-139.

[22] Dubreuil J,Rouset P.The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma.Nucl Med Commun2017;38:312-18

[23] Laterza R,Baratti D.Role of explorative laparoscopy to evaluate optimal candicates for cytoreductive surgery and hyperthermaic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma.In Vivo2009;23:187-90

[24] Baratti D,Deraco M.Circulating CA125 and diffuse malignant peritoneal mesothelioma.Eur J Surg Oncol2009;35:1198-9

[25] Ramp A,Tanaka M.Binding of ovarian cancer antigen CA125/MUC 16 to mesothelin mediated cell adhesion.J Biol Chem2004;279:9190-8

[26] Kaya H,Tanrıkulu AC.Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.Neoplasma2014;61:433-8

[27] Salo SAS,Laarksonen S.Malignant peritoneal mesothelioma: treatment options and survival.Anticancer Res2019;39:839-45

[28] Sugarbaker PH,Mohamed F.A review of peritoneal mesothelioma at the Washington Cancer Institute.Surg Oncol Clin N Am2003;12:605-21

[29] Baratti D,Cabras AD.Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by nyperthermic intraperitoneal chemotherapy (HIPEC).Eur J Cancer2013;49:3140-8

[30] Kepenekian V,Passot G.Diffuse naliganat peritoneal mesothelioma: evaluation od systemic chemotherapy with comprehensive treatment through the RENAPE database multi-institutional retrospective study.Euro J Cancer2016;65:69-79

[31] Alexander HR,Pingpank JF.Treatment factors associated with lon-term survival after cytoreductive surgery snd regional chemotherapy for patients with malignant peritoneal mesothelioma.Surgery2013;153:779-86

[32] Helm JH,Glenn JA.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.Ann Surg Oncol2015;22:1686-93

[33] Yonemura Y,Canbay E.Treatment results of diffuse malignant peritoneal mesothelioma.Gan Kagaku Ryoho2012;39:2416-9.

[34] Magge D,Austin F.Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.Ann Surg Oncol2014;21:1159-65 PMCID:PMC4100549

[35] Pavlisko EN.Sarcomatoid peritoneal mesothelioma: clinicopathologic correlation of 13 cases.Am J Surg Pathol2015;11:1568-75

[36] Naffouje S,Salti GI.The impact of chemotherapy and its timing on survival in malignanrt peritoneal mesothelioma treated with complete debulking.Med Onco2018;

[37] Deraco M,Hutanu I,Kusamura S.The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.Ann Surg Oncol2013;20:1093-100

[38] Lopock JR.Cellular effects of hyperthermia, relevance to the minimum dose for thermal damage.In J Hyperthermia2003;19:252-66

[39] Yonemura Y.Treatment of peritoneal metastasis from rare diseases: well-differentiated papillary peritoneal mesothelioma. Asian School of Peritoneal Surface Oncology: Japanese.2019. p.166-7.

[40] Le Roy F,Hollebecque A.Conversion to complete cytoreductionsurgery and hyperthermic intraperitoneal chemotherapy fornmaliganat peritoneal mesothelioma after bidirectional chemotherapy.Ann Surg Oncol2017;24:3640-6